This online CME course from the North American Thrombosis Forum provides a comprehensive review of the most significant changes and advances impacting the care of patients who have — or are at risk for — thrombotic disorders. World-renowned experts and leading clinical faculty share key updates on the prevention, diagnosis, and treatment of thrombosis and related conditions.
Thrombosis and Thromboembolism is continuing medical education that will help you to:
- Identify the etiology and pathophysiology of atherothrombosis
- Recognize the link between inflammation and thrombotic illnesses
- Explain new tools for stroke prevention and prediction in atrial fibrillation
- Identify the optimal duration of anticoagulation for PE and DVT
- Provide advanced therapies such as thrombolysis, catheter-directed therapy, and surgical embolectomy
- Explain the connection between diabetes, metabolic syndrome, and major adverse cardiac events
- Provide patients with useful insights into how a heart-healthy diet can help prevent thrombosis
- Manage a high-risk pregnancy
- And more…
Learning Objectives
At the conclusion of this activity, you will be able to:
- Identify the etiology and pathophysiology of atherothrombosis
- Recognize the link between inflammation and thrombotic illnesses
- Explain new tools for stroke prevention (and stroke prediction) in atrial fibrillation
- Identify the optimal duration of anticoagulation for PE and DVT
- Provide advanced therapy beyond anticoagulation in PE and DVT: thrombolysis, catheter-directed therapy, surgical embolectomy
- Explain the connection between diabetes, metabolic syndrome, and major adverse cardiac events
- Provide patients with useful insights into how a heart-healthy diet can help prevent thrombosis
- Manage a high-risk pregnancy
Intended Audience
This educational activity was designed for physicians, nurse practitioners (NPs), and physician assistants (PAs) interested in changes and advances impacting the care of patients who have or are at risk for thrombotic disorders.
TOPICS / SPEAKERS
Novel Targets For Atherosclerosis Prevention
What’s New with TG and AngPTL3 – Aruna D. Pradhan, MD, MPH, MSc
What’s New with Lp(a) – Samia Mora, MD
What’s New with LDL and ApoB – Jorge Plutzky, MD
What’s New with Inflammatory Targets – Paul M. Ridker, MD, MPH
Discussion/Q&A – John F. Keaney, Jr., MD – Moderator
Peripheral Arterial Disease
PAD – Pathways for Optimizing Cardiovascular and Limb Outcomes – Marc P. Bonaca, MD, MPH
Discussion/Q&A – Marie D. Gerhard-Herman, MD – Moderator
Heart Failure
Heart Failure and Venous Thromboembolism – Samuel Z. Goldhaber, MD
More Than Just Diabetes and Heart Failure – SGLT2 – Deepak L. Bhatt, MD, MPH
More Than Just Diabetes and Heart Failure – GLP1 – Brendan M. Everett, MD, MPH
Heart Failure – Reduced Ejection Fraction – Marc A. Pfeffer, MD, PhD
Discussion/Q&A – Akshay Suvas Desai, MD, MPH – Moderator
Heart Failure – Preserved Ejection Fraction – Scott D. Solomon, PhD
Heart Failure – Middle-of-the-Road Ejection Fraction – Navigating the Alphabet Soup – Michele A. Hamilton, MD
CMR Imaging of Imaging of Heart Failure – Raymond Y. Kwong, MD, MPH
Atrial Fibrillation & Coronary Disease
Dual Antiplatelet Therapy and Anticoagulation – Michelle L. O’Donoghue, MD, MPH
How to Manage the Anticoagulation Around Ablation and Cardioversions and Watchmans for AF – Bruce A. Koplan, MD
Anticoagulation
Dose-Reduced Direct Oral Anticoagulants – Efficacy and Safety – Behnood Bikdeli, MD, MS
Duration of Anticoagulation – Arterial Thrombosis – Navigating Limitations in Data and Variations in Practice – Teresa Carman, MD, RPVI, MSVM
Duration of Anticoagulation – Venous Thrombosis – Gregory Piazza, MD, MS
Novel Anticoagulation Targets – Factor XI and XII Inhibitors – Jeffrey I. Weitz, MD
Discussion/Q&A – Samuel Z. Goldhaber, MD – Moderator
Racial Disparities In Arterial And Venous Thrombosis
Racial Disparities in Healthcare – Cassandra M. Pierre, MD, MSc
Racial Disparities in Arterial and Venous Thrombosis – Karlyn A. Martin, MD
Discussion/Q&A – Gregory Piazza, MD, MS – Moderator
Genetics
VTE Prediction – Using Genetics as a Powerful Tool – Nicholas A. Marston, MD, MPH
Clonal Hematopoiesis of Indeterminate Potential (CHIP) – Association with VTE & PAD – Peter Libby, MD
Discussion/Q&A – Gregory Piazza, MD, MS – Moderator
Covid And Thrombosis
COVID and Thrombosis – Mechanisms and Epidemiology – Gregory Piazza, MD, MS
Prevention of VTE in COVID-19 Patients – Behnood Bikdeli, MD, MS
Discussion/Q&A – Samuel Z. Goldhaber, MD – Moderator
VTE Prevention
VTE Prophylaxis for Orthopedic Surgery – Samuel Z. Goldhaber, MD
Discussion/Q&A – Ebrahim Barkoudah, MD, MPH – Moderator
PE Reperfusion
Device Therapy for PE Reperfusion – Navigating a Rapidly Changing Landscape – Gregory Piazza, MD, MS
Systemic Fibrinolysis (PEITHO-3) – Samuel Z. Goldhaber, MD
Adventures with Hypertrophic Cardiomyopathy – 1958-2022 – Eugene Braunwald, MD
Pulmonary Hypertension and Thrombosis
Chronic Thromboembolic Pulmonary Hypertension – Bradley A. Maron, MD
Pulmonary Hypertension After PE That is Not Chronic Thromboembolic Pulmonary Hypertension – Jane A. Leopold, MD, FACC, FAHA, FSCAIc
Post-Thrombotic Syndrome
Post-thrombotic Syndrome – Epidemiology and Medical Therapy – Susan R. Kahn, MD, MSc, FRCPC, ABIM
Intervention, Acute Intervention, and Chronic Venous Obstructive Disease – Suresh Vedantham, MD
Discussion/Q&A – Arvind K. Pandey, MD – Moderator
VTE and Cancer
Vascular Cardio-Oncology – Javid Moslehi, MD
Prevention of Thrombotic Complications of Cancer and Cancer Therapy – Simon Mantha, MD, MPH
Treatment of Cancer-Associated Thrombosis – Michael B. Streiff, MD
Discussion/Q&A – Jean Connors, MD – Moderator
Date of Original Release: December 31, 2022
Reviews
There are no reviews yet.